Study Group: Lipitor Prescribers for Hypercholesterolemia (US)(?)
Council Members in this Study Group: 59
Request a survey with this Study Group
Leading Experts in this Study Group
Professor of Medicine
Finch University of Health Science-Chicago Medical School
Rohit Arora, MD, FACC, FAHA, FASCI, FACP, is a Professor of Medicine and Professor of Physiology and Biophysics at Chicago Medical School, Illinois. He is also the Chairman of Cardiology and Associate Chairman of Medicine in the Department of Medicine. Dr. Arora is also Chief of Cardiology at the North...
Clinical Director
NYU Medical Center
Howard Weintraub, MD, FACC, is the Clinical Director of Center for the Prevention of Cardiovascular Disease at NYU Medical Center. He has been a consultant for several organizations and has been a Cardiologist for the National Football League. Dr. Weintraub has written textbook chapters on evaluation...
Michael Davidson, MD, FACCDirector, Preventive Cardiology
The University of Chicago
Michael Davidson, MD, FACC, is Executive Medical Director at Radiant Research, Director of Preventive Cardiology and Clinical Professor of Medicine at the University of Chicago Pritzker School of Medicine. In addition, he is Founder, President, and Chief Executive Officer of the Chicago Center for Clinical...
Harold Bays, MD, FACPPresident and Medical Director
L-MARC Research Center
Harold Bays, MD, FACE, FACP, is Medical Director and President of Louisville Metabolic and Atherosclerosis Research Center (L-MARC), a metabolic clinical research facility that has conducted over 400 phase I-IV clinical trials, including studies of all marketed lipid-altering drug treatments, as well...
Hossein Ardehali, MD, PhDAssistant Professor
Feinberg School of Medicine, Northwestern University
Hossein Ardehali, MD, PhD, is an Assistant Professor of Medicine at Feinberg Cardiovascular Institute in Illinois. His specialties include lipid metabolism, preventive cardiology, electrophysiology and heart failure. Dr. Ardehali's basic science research interest is in the areas of reperfusion injury...
Cardiologist
NYU Medical Center
Daniel Fisher, MD, FACC, FACP, is a Cardiologist at NYU Medical Center. He has a private practice in Cardiology and specializes in non-invasive cardiology. Dr. Fisher is board certified in Internal Medicine, Cardiovascular Diseases, and Nuclear Cardiology. He has lectured frequently on such topics as...
Owner
Joshua M. Feuer, MD
Joshua Feuer, MD, FACC, is a board certified Cardiologist in solo private practice in Santa Barbara, California. He also serves as a Consulting Cardiologist at Santa Barbara Cottage Hospital. Dr. Feuer specializes in aggressive preventive cardiology and cardiovascular risk assessment and reduction....
Charles Glueck, MDMedical Research Director of Cholesterol Center
Jewish Hospital
Charles Glueck, MD, is the Medical Director of Jewish Hospital Cholesterol Center in Cincinnati, Ohio. He has expertise in lipids, lipoproteins, interaction of atherosclerosis and thrombosis, thrombosis, human genetics, epidemiology, obstetrics and gynecology, and hematology. Dr Glueck and colleagues...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The Medicare drug system was a political ploy. This just confrims it. The private insurers were unwilling to offer Rx coverage before then because they understood the economics of it.
Given the economic pressures on patients, they are now more likely to ask for generic medications than they were in the past. Given that there are generic versions of several classes of medications, physicians such as me are more likely to comply with a patient's request for a generic than in...
I am a heavy user of ARB's and Tekturna. This article does not really show anything of significance. Most practicing physicians have seen much better results and much better tolerability with ARB's than diuretics. I do not think this is going to change prescribing habits of anyone. ...
It is well known that the addition of thiazide diuretic to ACEI or ARB treatment adds about 10 mm Hg reduction on top of the 10 mm Hg reduction provided by the ACEI or ARB agent. It is expected that blocking renin in the renin angiotensin system with Tekturna would provide a similar result.
I anticipate vytorin and zetia sales will be down substantial when the IMS numbers come out tommorrow, but that this will be only the beginning of a negative trend for these scripts. I list below several reasons why.
Most Common Company Types:
- Office Based Private Practice or Clinic
- Academic Medical Center/Hospital or Clinic
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
- Contract Research Organization, Independent/Small
- Other Freestanding Healthcare Facility
Most Common Job Types:
- Physician - Attending Physician
- Owner
- Physician - Director
- Medical Director
- Physician - Department Chair
- President
- Physician - Division Head
- Partner
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms